WednesdayApr 13, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable

Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1 SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments to patients nationwide Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), through its wholly-owned subsidiary, Delic Labs, has remained committed to expanding its ability to research novel compounds and developing intellectual property (“IP”) for future commercialization of novel psychedelic compounds for medical use. So far,…

Continue Reading

TuesdayApr 12, 2022 2:17 pm

Legislators in Colorado Pass MDMA Initiative But Reject Broader Psychedelics Proposal

Earlier last week, legislators in Colorado passed a measure that aligns statutes in the state to legalize MDMA prescriptions if the federal government allows its use. MDMA, which is commonly referred to as ecstasy, has shown promise in its use as a treatment for various indications, including anxiety and PTSD. The legislators made their decision after hearing testimonies from a number of people, including a military veteran who admitted that MDMA had helped him manage his post-traumatic stress disorder. This measure, which was unanimously approved, is being advanced to the floor. The House Public & Behavioral Health & Human Services…

Continue Reading

TuesdayApr 12, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements

In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in 2021 With new additions to its board, its conditional IRB approval, and the clinical research it has lined up for the new year, Mydecine is confident that it will meet its anticipated capital markets initiatives for 2022 Founded in 2020, Mydecine Innovations Group (NEO: MYCO)…

Continue Reading

MondayApr 11, 2022 2:50 pm

Top Federal Official Highlights Need to Enact Policy Changes for More Psychedelic Research to Be Conducted

During an event last week, top drug officials explained how the classification of substances such as cannabis and some psychedelics under Schedule I of the Controlled Substances Act hindered studies into the therapeutic potential of these substances from being conducted. The event, which focused on treatment using psychedelics, was organized by the National Academies of Sciences, Engineering and Medicine. Nora Volkow, director of the National Institute on Drug Abuse, has addressed the stressful process that researchers have to go through in order to acquire these controlled substances. During the event, Volkow explained that the scheduling process had made it hard…

Continue Reading

MondayApr 11, 2022 9:00 am

Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’

Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine” Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution Is Coming,” proclaims a “New York Times” article, which notes that as a result, psychiatry may never be the same. This isn’t news for companies such as Silo Pharma (OTCQB: SILO). A developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, Silo…

Continue Reading

FridayApr 08, 2022 3:12 pm

Oregon Health Authority Admits Proposed Psilocybin Rules May Negatively Impact Lower-Income Individuals

Recently, the Oregon Health Authority announced its latest revision of proposed rules at the start of this month. The rules were released ahead of the state’s psilocybin services program, which is scheduled to open to the private and public business sector in early 2023. Regarding its proposal, the Oregon Health Authority stated that the rules would impact all psilocybin testing laboratories, psilocybin facilitators, psilocybin service centers, psilocybin manufacturers and psilocybin training programs in the state. These rules, which focus on the manufacture and testing of psilocybin products and training modules for aspiring licensed facilitators, may have a negative effect on…

Continue Reading

FridayApr 08, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030 One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN)…

Continue Reading

ThursdayApr 07, 2022 3:01 pm

UNC Professor Reveals Personal Motive in Studying Psychedelics for Mental Health

Professor Bryan Roth of the University of North Carolina at Chapel Hill says that psychedelic drugs had demonstrated in studies that they had miraculous effects on mental illnesses. Roth also revealed that his research was personal, explaining that his mother suffered from schizophrenia all her life, having had her first episode when he was about five. This, Roth said, has motivated him to learn more about what goes on in the brain. Schizophrenia is a severe mental disorder in which individuals interpret reality in an abnormal way. Patients suffer from delusions, hallucinations and disordered behavior and thinking. After being legally…

Continue Reading

WednesdayApr 06, 2022 3:09 pm

How You Can Participate in a Psychedelic Clinical Trial

These last few years, clinical trials on the use of psychedelics such as MDMA, LSD or psilocybin as treatments for various mental health conditions have increased significantly. For clinical trials to run, however, participants are needed. At first glance, it may seem easy to enroll individuals for trials given that quite a number of people suffer from mental conditions such as depression and anxiety. However, for an individual to be enrolled into a clinical trial, they must meet the stipulated inclusion criteria in order to be eligible. Below are steps on how one can enroll in a psychedelic clinical trial.…

Continue Reading

TuesdayApr 05, 2022 3:29 pm

Ibogaine Blocks Reward Pathways in Alcohol-Dependent Mice

New research has found that ibogaine blocks some of the abuse-related effects of alcohol in mice. Ibogaine is a natural product extracted from the Tabernanthe iboga plant. It is commonly used during religious ceremonies in the form of tea and is extracted from the plant’s root, bark and stem. Alcohol use disorder is a chronic illness that is characterized by uncontrollable drinking. Symptoms include the repeated consumption of alcohol despite related health and legal problems. This disorder is a leading cause of death and absenteeism globally and is recognized as a global public health issue. However, the current treatments used…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000